Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Journal
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion.

The Journal of pharmacy and pharmacology

Ross AC, MacRae RJ, Walther M, Stevens HN.
PMID: 11007060
J Pharm Pharmacol. 2000 Aug;52(8):903-9. doi: 10.1211/0022357001774787.

We report the development of a chronopharmaceutical capsule drug delivery system capable of releasing drug after pre-determined time delays. The drug formulation is sealed inside the insoluble capsule body by an erodible tablet (ET). The release time is determined...

Cite
Ross AC, MacRae RJ, Walther M, et al. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol. 2000;52(8):903-9doi: 10.1211/0022357001774787.
Ross, A. C., MacRae, R. J., Walther, M., & Stevens, H. N. (2000). Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. The Journal of pharmacy and pharmacology, 52(8), 903-9. https://doi.org/10.1211/0022357001774787
Ross, A C, et al. "Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion." The Journal of pharmacy and pharmacology vol. 52,8 (2000): 903-9. doi: https://doi.org/10.1211/0022357001774787
Ross AC, MacRae RJ, Walther M, Stevens HN. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol. 2000 Aug;52(8):903-9. doi: 10.1211/0022357001774787. PMID: 11007060.
Copy Download .nbib Format: NLM
The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

McConville JT, Ross AC, Chambers AR, Smith G, Florence AJ, Stevens HN.
PMID: 15093604
Eur J Pharm Biopharm. 2004 May;57(3):541-9. doi: 10.1016/j.ejpb.2004.01.004.

The purpose of this study was to investigate the variability in the performance of a pulsatile capsule delivery system induced by wet granulation of an erodible HPMC tablet, used to seal the contents within an insoluble capsule body. Erodible...

Cite
McConville JT, Ross AC, Chambers AR, et al. The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. Eur J Pharm Biopharm. 2004;57(3):541-9doi: 10.1016/j.ejpb.2004.01.004.
McConville, J. T., Ross, A. C., Chambers, A. R., Smith, G., Florence, A. J., & Stevens, H. N. (2004). The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 57(3), 541-9. https://doi.org/10.1016/j.ejpb.2004.01.004
McConville, Jason T, et al. "The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 57,3 (2004): 541-9. doi: https://doi.org/10.1016/j.ejpb.2004.01.004
McConville JT, Ross AC, Chambers AR, Smith G, Florence AJ, Stevens HN. The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. Eur J Pharm Biopharm. 2004 May;57(3):541-9. doi: 10.1016/j.ejpb.2004.01.004. PMID: 15093604.
Copy Download .nbib Format: NLM
Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier.

International journal of pharmaceutics

Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM.
PMID: 15652198
Int J Pharm. 2005 Jan 31;289(1):51-62. doi: 10.1016/j.ijpharm.2004.10.022. Epub 2004 Dec 30.

Lyophilised wafers have potential as drug delivery systems for suppurating wounds. A dual series of wafers made from low molecular weight sodium alginate (SA) and xanthan gum (XG) respectively, modified with high molecular weight methylcellulose (MC) were produced. The...

Cite
Matthews KH, Stevens HN, Auffret AD, et al. Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier. Int J Pharm. 2004;289(1):51-62doi: 10.1016/j.ijpharm.2004.10.022.
Matthews, K. H., Stevens, H. N., Auffret, A. D., Humphrey, M. J., & Eccleston, G. M. (2005). Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier. International journal of pharmaceutics, 289(1), 51-62. https://doi.org/10.1016/j.ijpharm.2004.10.022
Matthews, K H, et al. "Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier." International journal of pharmaceutics vol. 289,1 (2005): 51-62. doi: https://doi.org/10.1016/j.ijpharm.2004.10.022
Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM. Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier. Int J Pharm. 2005 Jan 31;289(1):51-62. doi: 10.1016/j.ijpharm.2004.10.022. Epub 2004 Dec 30. PMID: 15652198.
Copy Download .nbib Format: NLM
Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

McInnes FJ, O'Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, Stevens HN.
PMID: 17368006
Eur J Pharm Sci. 2007 May;31(1):25-31. doi: 10.1016/j.ejps.2007.02.002. Epub 2007 Feb 11.

Bioadhesive dosage forms are a potential method for overcoming rapid mucociliary transport in the nose. A lyophilised nasal insert formulation previously investigated in sheep demonstrated prolonged absorption of nicotine hydrogen tartrate suggestive of extended nasal residence, and increased bioavailability....

Cite
McInnes FJ, O'Mahony B, Lindsay B, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci. 2007;31(1):25-31doi: 10.1016/j.ejps.2007.02.002.
McInnes, F. J., O'Mahony, B., Lindsay, B., Band, J., Wilson, C. G., Hodges, L. A., & Stevens, H. N. (2007). Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 31(1), 25-31. https://doi.org/10.1016/j.ejps.2007.02.002
McInnes, Fiona J, et al. "Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy." European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences vol. 31,1 (2007): 25-31. doi: https://doi.org/10.1016/j.ejps.2007.02.002
McInnes FJ, O'Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, Stevens HN. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci. 2007 May;31(1):25-31. doi: 10.1016/j.ejps.2007.02.002. Epub 2007 Feb 11. PMID: 17368006.
Copy Download .nbib Format: NLM
Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract.

Current medical research and opinion

Stevens HN, Speakman M.
PMID: 17257446
Curr Med Res Opin. 2006 Dec;22(12):2323-8. doi: 10.1185/030079906X154051.

OBJECTIVE: To assess the in vivo behaviour, gastric emptying time and gastrointestinal transit of the new tablet formulation of tamsulosin which uses the Oral Controlled Absorption System (OCAS) technology and to relate gastrointestinal transit parameters to the profile of...

Cite
Stevens HN, Speakman M. Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. Curr Med Res Opin. 2006;22(12):2323-8doi: 10.1185/030079906X154051.
Stevens, H. N., & Speakman, M. (2006). Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. Current medical research and opinion, 22(12), 2323-8. https://doi.org/10.1185/030079906X154051
Stevens, H N E, and Speakman, M. "Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract." Current medical research and opinion vol. 22,12 (2006): 2323-8. doi: https://doi.org/10.1185/030079906X154051
Stevens HN, Speakman M. Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. Curr Med Res Opin. 2006 Dec;22(12):2323-8. doi: 10.1185/030079906X154051. PMID: 17257446.
Copy Download .nbib Format: NLM
Gamma-irradiation of lyophilised wound healing wafers.

International journal of pharmaceutics

Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM.
PMID: 16503387
Int J Pharm. 2006 Apr 26;313(1):78-86. doi: 10.1016/j.ijpharm.2006.01.023. Epub 2006 Feb 28.

Lyophilised wafers are being developed as drug delivery systems that can be applied directly to the surface of suppurating wounds. They are produced by the freeze-drying of polymer solutions and gels. This study investigates the possibility of sterilising these...

Cite
Matthews KH, Stevens HN, Auffret AD, et al. Gamma-irradiation of lyophilised wound healing wafers. Int J Pharm. 2006;313(1):78-86doi: 10.1016/j.ijpharm.2006.01.023.
Matthews, K. H., Stevens, H. N., Auffret, A. D., Humphrey, M. J., & Eccleston, G. M. (2006). Gamma-irradiation of lyophilised wound healing wafers. International journal of pharmaceutics, 313(1), 78-86. https://doi.org/10.1016/j.ijpharm.2006.01.023
Matthews, K H, et al. "Gamma-irradiation of lyophilised wound healing wafers." International journal of pharmaceutics vol. 313,1 (2006): 78-86. doi: https://doi.org/10.1016/j.ijpharm.2006.01.023
Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM. Gamma-irradiation of lyophilised wound healing wafers. Int J Pharm. 2006 Apr 26;313(1):78-86. doi: 10.1016/j.ijpharm.2006.01.023. Epub 2006 Feb 28. PMID: 16503387.
Copy Download .nbib Format: NLM
Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy.

Pharmaceutical research

Kelly K, O'Mahony B, Lindsay B, Jones T, Grattan TJ, Rostami-Hodjegan A, Stevens HN, Wilson CG.
PMID: 14620524
Pharm Res. 2003 Oct;20(10):1668-73. doi: 10.1023/a:1026155822121.

PURPOSE: To investigate the hypothesis that faster drug absorption from a new paracetamol formulation containing sodium bicarbonate compared to that from a conventional formulation results from a combination of enhanced gastric emptying and disintegration/dissolution.METHODS: Each formulation was administered in...

Cite
Kelly K, O'Mahony B, Lindsay B, et al. Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res. 2003;20(10):1668-73doi: 10.1023/a:1026155822121.
Kelly, K., O'Mahony, B., Lindsay, B., Jones, T., Grattan, T. J., Rostami-Hodjegan, A., Stevens, H. N., & Wilson, C. G. (2003). Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharmaceutical research, 20(10), 1668-73. https://doi.org/10.1023/a:1026155822121
Kelly, Kilian, et al. "Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy." Pharmaceutical research vol. 20,10 (2003): 1668-73. doi: https://doi.org/10.1023/a:1026155822121
Kelly K, O'Mahony B, Lindsay B, Jones T, Grattan TJ, Rostami-Hodjegan A, Stevens HN, Wilson CG. Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res. 2003 Oct;20(10):1668-73. doi: 10.1023/a:1026155822121. PMID: 14620524.
Copy Download .nbib Format: NLM
A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers.

Journal of pharmaceutical sciences

McConville JT, Hodges LA, Jones T, Band JP, O'Mahony B, Lindsay B, Ross AC, Florence AJ, Stanley AJ, Humphrey MJ, Wilson CG, Stevens HN.
PMID: 19387976
J Pharm Sci. 2009 Nov;98(11):4251-63. doi: 10.1002/jps.21739.

Three time-delayed capsule (TDC) formulations were investigated in a pharmacoscintigraphic study, using a three-way crossover design in eight healthy male volunteers. Additionally, the pulsed release of a TDC was investigated with time-lapse photography, using a nondisintegrating riboflavin tablet. The...

Cite
McConville JT, Hodges LA, Jones T, et al. A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. J Pharm Sci. 2009;98(11):4251-63doi: 10.1002/jps.21739.
McConville, J. T., Hodges, L. A., Jones, T., Band, J. P., O'Mahony, B., Lindsay, B., Ross, A. C., Florence, A. J., Stanley, A. J., Humphrey, M. J., Wilson, C. G., & Stevens, H. N. (2009). A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. Journal of pharmaceutical sciences, 98(11), 4251-63. https://doi.org/10.1002/jps.21739
McConville, Jason T, et al. "A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers." Journal of pharmaceutical sciences vol. 98,11 (2009): 4251-63. doi: https://doi.org/10.1002/jps.21739
McConville JT, Hodges LA, Jones T, Band JP, O'Mahony B, Lindsay B, Ross AC, Florence AJ, Stanley AJ, Humphrey MJ, Wilson CG, Stevens HN. A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. J Pharm Sci. 2009 Nov;98(11):4251-63. doi: 10.1002/jps.21739. PMID: 19387976.
Copy Download .nbib Format: NLM
Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant.

International journal of pharmaceutics

Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM.
PMID: 18280068
Int J Pharm. 2008 May 22;356(1):110-20. doi: 10.1016/j.ijpharm.2007.12.043. Epub 2008 Jan 09.

Lyophilised wafers are being developed as topical drug delivery systems for the treatment of chronic wounds. This study describes the formulation of xanthan wafers containing a selective, insoluble MMP-3 inhibitor (UK-370,106) and a non-ionic surfactant, designed to release accurate...

Cite
Matthews KH, Stevens HN, Auffret AD, et al. Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant. Int J Pharm. 2008;356(1):110-20doi: 10.1016/j.ijpharm.2007.12.043.
Matthews, K. H., Stevens, H. N., Auffret, A. D., Humphrey, M. J., & Eccleston, G. M. (2008). Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant. International journal of pharmaceutics, 356(1), 110-20. https://doi.org/10.1016/j.ijpharm.2007.12.043
Matthews, K H, et al. "Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant." International journal of pharmaceutics vol. 356,1 (2008): 110-20. doi: https://doi.org/10.1016/j.ijpharm.2007.12.043
Matthews KH, Stevens HN, Auffret AD, Humphrey MJ, Eccleston GM. Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant. Int J Pharm. 2008 May 22;356(1):110-20. doi: 10.1016/j.ijpharm.2007.12.043. Epub 2008 Jan 09. PMID: 18280068.
Copy Download .nbib Format: NLM
A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease.

Molecular pharmaceutics

Pritchard MF, Powell LC, Menzies GE, Lewis PD, Hawkins K, Wright C, Doull I, Walsh TR, Onsøyen E, Dessen A, Myrvold R, Rye PD, Myrset AH, Stevens HN, Hodges LA, MacGregor G, Neilly JB, Hill KE, Thomas DW.
PMID: 26833139
Mol Pharm. 2016 Mar 07;13(3):863-72. doi: 10.1021/acs.molpharmaceut.5b00794. Epub 2016 Feb 16.

The host- and bacteria-derived extracellular polysaccharide coating of the lung is a considerable challenge in chronic respiratory disease and is a powerful barrier to effective drug delivery. A low molecular weight 12-15-mer alginate oligosaccharide (OligoG CF-5/20), derived from plant...

Cite
Pritchard MF, Powell LC, Menzies GE, et al. A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. Mol Pharm. 2016;13(3):863-72doi: 10.1021/acs.molpharmaceut.5b00794.
Pritchard, M. F., Powell, L. C., Menzies, G. E., Lewis, P. D., Hawkins, K., Wright, C., Doull, I., Walsh, T. R., Onsøyen, E., Dessen, A., Myrvold, R., Rye, P. D., Myrset, A. H., Stevens, H. N., Hodges, L. A., MacGregor, G., Neilly, J. B., Hill, K. E., & Thomas, D. W. (2016). A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. Molecular pharmaceutics, 13(3), 863-72. https://doi.org/10.1021/acs.molpharmaceut.5b00794
Pritchard, Manon F, et al. "A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease." Molecular pharmaceutics vol. 13,3 (2016): 863-72. doi: https://doi.org/10.1021/acs.molpharmaceut.5b00794
Pritchard MF, Powell LC, Menzies GE, Lewis PD, Hawkins K, Wright C, Doull I, Walsh TR, Onsøyen E, Dessen A, Myrvold R, Rye PD, Myrset AH, Stevens HN, Hodges LA, MacGregor G, Neilly JB, Hill KE, Thomas DW. A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. Mol Pharm. 2016 Mar 07;13(3):863-72. doi: 10.1021/acs.molpharmaceut.5b00794. Epub 2016 Feb 16. PMID: 26833139.
Copy Download .nbib Format: NLM
Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces.

Drug development and industrial pharmacy

Boateng JS, Stevens HN, Eccleston GM, Auffret AD, Humphrey MJ, Matthews KH.
PMID: 19365780
Drug Dev Ind Pharm. 2009 Aug;35(8):986-96. doi: 10.1080/03639040902744704.

Solvent-cast films from three polymers, carboxymethylcellulose (CMC), sodium alginate (SA), and xanthan gum, were prepared by drying the polymeric gels in air. Three methods, (a) passive hydration, (b) vortex hydration with heating, and (c) cold hydration, were investigated to...

Cite
Boateng JS, Stevens HN, Eccleston GM, et al. Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces. Drug Dev Ind Pharm. 2009;35(8):986-96doi: 10.1080/03639040902744704.
Boateng, J. S., Stevens, H. N., Eccleston, G. M., Auffret, A. D., Humphrey, M. J., & Matthews, K. H. (2009). Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces. Drug development and industrial pharmacy, 35(8), 986-96. https://doi.org/10.1080/03639040902744704
Boateng, Joshua S, et al. "Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces." Drug development and industrial pharmacy vol. 35,8 (2009): 986-96. doi: https://doi.org/10.1080/03639040902744704
Boateng JS, Stevens HN, Eccleston GM, Auffret AD, Humphrey MJ, Matthews KH. Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces. Drug Dev Ind Pharm. 2009 Aug;35(8):986-96. doi: 10.1080/03639040902744704. PMID: 19365780.
Copy Download .nbib Format: NLM
Intramuscular formulations of fluphenazine and their duration of activity in the rat [proceedings].

The Journal of pharmacy and pharmacology

Florence AT, Vezin WR, Ray-Johnson ML, Stevens HN.
PMID: 32282
J Pharm Pharmacol. 1978 Dec;30:28P. doi: 10.1111/j.2042-7158.1978.tb10735.x.

No abstract available.

Cite
Florence AT, Vezin WR, Ray-Johnson ML, et al. Intramuscular formulations of fluphenazine and their duration of activity in the rat [proceedings]. J Pharm Pharmacol. 1978;30:28Pdoi: 10.1111/j.2042-7158.1978.tb10735.x.
Florence, A. T., Vezin, W. R., Ray-Johnson, M. L., & Stevens, H. N. (1978). Intramuscular formulations of fluphenazine and their duration of activity in the rat [proceedings]. The Journal of pharmacy and pharmacology, 3028P. https://doi.org/10.1111/j.2042-7158.1978.tb10735.x
Florence, A T, et al. "Intramuscular formulations of fluphenazine and their duration of activity in the rat [proceedings]." The Journal of pharmacy and pharmacology vol. 30 (1978): 28P. doi: https://doi.org/10.1111/j.2042-7158.1978.tb10735.x
Florence AT, Vezin WR, Ray-Johnson ML, Stevens HN. Intramuscular formulations of fluphenazine and their duration of activity in the rat [proceedings]. J Pharm Pharmacol. 1978 Dec;30:28P. doi: 10.1111/j.2042-7158.1978.tb10735.x. PMID: 32282.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries